The Medicines and Health Products Regulatory Agency (MHRA) reported that the decision was made after a "rigorous review" of the safety and effectiveness of the preparation for these children.
"We have carefully reviewed data from clinical trials in children ages 12-15 years and have concluded that the Pfizer / BioNTech COVID-19 vaccine is safe and effective for this age group and that the benefits of this vaccine outweigh any risk"MHRA Executive Director June Raine said in a statement released Friday.
Raine added that the MHRA has special measures in place to closely monitor the safety of all COVID-19 vaccines approved in the UK.
The preparations would not be approved unless they meet the necessary "safety, quality and effectiveness", he added.
This approval was announced after health authorities reported that half of adults have received both doses of a COVID-19 vaccine, while 75.2% of the adult population has been vaccinated with the first dose.
The country, which started the immunization plan last December, is vaccinating with preparations from AstraZeneca, Pfizer and Moderna.